Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib Trial of MBF-362 in Solid Tumors
NCT05940571Phase 1Completed
- Sponsor
- Medibiofarma
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MBF-362 in solid tumor (4 arms), sponsored by Medibiofarma. Primary endpoints: Number of Adverse Events at 28 Days and Maximum Tolerated Dose at 28 Days. Started Nov 2022; status: completed.
02
Drugs
MBF-362
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05940571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940571.